Abstract
2-Chloro-N 6-methyl-(N )-methanocarba-2′-deoxyadenosine-3′,5′- bisphosphate (MRS2279) was developed previously as a selective high-affinity, non-nucleotide P2Y1 receptor (P2Y1-R) antagonist (J Med Chem 43:829–842, 2002; Br J Pharmacol 135:2004–2010, 2002). We have taken advantage of theN 6-methyl substitution in the adenine base to incorporate [3H]methylamine into the synthesis of [3H]MRS2279 to high (89 Ci/mmol) specific radioactivity and have used this molecule as a radioligand for the P2Y1-R. [3H]MRS2279 bound to membranes from Sf9 insect cells expressing recombinant human P2Y1-R but not to membranes from wild-type Sf9 cells or Sf9 cells expressing high levels of recombinant P2Y2 or P2Y12 receptors. Equilibrium binding of [3H]MRS2279 to P2Y1-R expressed in Sf9 membranes was with a high affinity (K d= 8 nM) essentially identical to the apparent affinity of MRS2279 determined previously in studies of P2Y1-R–promoted inositol phosphate accumulation or platelet aggregation. A kinetically derivedK d calculated from independent determinations of the rate constants of association (7.15 × 107 M−1min−1) and dissociation (0.72 min−1) of [3H]MRS2279 also was in good agreement with the K dderived from equilibrium binding studies. Competition binding assays with [3H]MRS2279 and P2Y1-R expressing Sf9 cell membranes revealed K i values for the P2Y1-R antagonists MRS2279 (K i = 13 nM),N 6-methyl-2′-deoxyadenosine-3′,5′-bisphosphate (MRS2179; K i = 84 nM), adenosine-3′, 5′-bisphosphate (K i=900 nM), and pyridoxal phosphate-6-azophenyl-2′,4′-disulfonic acid (K i = 6 μM) that were in good agreement with antagonist activities of these molecules previously determined at the P2Y1-R in intact tissues. Moreover, [3H]MRS2279 also bound with high affinity (K d = 4–8 nM) to Chinese hamster ovary (CHO) or 1321N1 human astrocytoma cells stably expressing the human P2Y1-R, but specific binding was not observed in wild-type CHO or 1321N1 cells. [3H]MRS2279 bound with high affinity (K d = 16 nM) to a binding site on out-dated human platelets (5–35 receptors/platelet) and rat brain membranes (210 fmol/mg protein) that fit the expected drug selectivity of a P2Y1-R. Taken together, these results indicate that [3H]MRS2279 is the first broadly applicable antagonist radioligand for a P2Y receptor.
- U.S. Government
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|